BIOGEN INC. Q3 FY2026 earnings call

• Strong Commercial Momentum: The growth portfolio has exceeded the legacy MS portfolio for consecutive quarters. The Appellus acquisition integration is proceeding faster than expected, with cost synergies identified earlier than planned.
• Pipeline Acceleration: Biogen has achieved five INDs in a single year for the first time in its history. Upcoming Phase III readouts for litofilumab (SLE/CLE) are scheduled for December, followed by data for talzadumab (AMR) and zorobinersen (Dravet syndrome).
• Market Creation Strategy: Management emphasizes building new markets in AMR and MVI rather than just taking share. In lupus, Biogen aims to overcome physician conservatism by educating on earlier biologic use, leveraging its strong patient services infrastructure from the MS business.
• Research Overhaul: A radical overhaul of early-stage development has shifted the company from an asset-by-asset approach to a portfolio-based strategy, aiming for at least 20 programs in early-stage development over the next few years.

Total core pharmaceutical revenue reached $2 billion, an 18% year-over-year increase. The growth portfolio contributed approximately $1.3 billion (63% of core revenue), up 49% year-over-year. Key product performances include: Spinraza ($461 million, +23% YoY); Sifovri ($191 million, +27% YoY); Vumerity ($192 million, -11% YoY); Lakembi ($202 million, +67% YoY); SkyClarus ($178 million, +34% YoY); and Empaveli ($52 million, +11% QoQ). The legacy MS portfolio (Casabri) generated $437 million, up 1% year-over-year.

• Full Year 2026 Non-GAAP Diluted EPS: Raised lower end of the range to $12.20–$13.00, driven by faster synergy capture from the Appellus acquisition and favorable commercial execution.
• Revenue Expectations: Expects return to top-line growth in 2026. Q4 revenue for key products like Sifovri and Vumerity is expected to be up mid-single digits or flat sequentially, reflecting normalization after Q3 tailwinds from Spinraza high-dose conversions and inventory dynamics.
• Expense Outlook: Core OpEx will reflect typical Q4 seasonality and continued investment in late-stage pipeline advancement. Approximately $50 million in acquired IPR&D charges are expected in Q4.

• Formulary Dynamics: Vumerity revenue was negatively impacted by tighter Part D formulary management, a trend expected to persist industry-wide.
• Patient Discontinuation: High discontinuation rates remain a challenge for Sifovri (after month one) and historically for SkyClarus, requiring targeted education campaigns for patients and physicians.
• Clinical Trial Heterogeneity: Lupus trials face challenges due to disease heterogeneity; success depends on managing background standard-of-care medications and steroid tapering protocols.
• Integration Distraction: While integration is going well, bolt-on acquisitions inevitably bring distraction risks that must be managed against core business performance.

Q: Analyst asked about the confidence in upcoming SLE data for litofilumab and differences between Phase II and III designs.

A: Priya Singhal acknowledged lupus's heterogeneity but stated that strategies like steroid tapering and controlling background meds have been optimized. She confirmed both Phase III SLE studies are on track for disclosure in the first half of December, without adding new strategic details beyond existing risk acknowledgments.

Q: Analyst queried the market development rate and ramp for Pulsar TNAB (talzadumab) in the AMR space, asking if Wall Street models are accurate.

A: Alicia Alimo explained that AMR is a ~11,000-patient market treated primarily in transplant centers. The ramp will be gradual as centers adopt protocols, but there is an immediate 'bolus' of existing patients. She noted that pricing will reflect significant value, supported by a dosing schedule that reduces doses in Year 2, similar to Spinraza's model.

Q: Analyst asked how much Syfovre injection growth is due to reducing free drug use vs. demand, and what barriers remain for discontinuation.

A: Alicia Alimo attributed growth to improved HCP sentiment regarding GA treatment and slowing lesion progression, not just free goods reduction. The primary barrier to retention is patient misunderstanding of efficacy; patients expect rapid clearing like wet AMD treatments. Biogen plans to launch DTC campaigns to educate patients on the drug's mechanism of slowing progression rather than immediate cure.

Q: Analyst asked about capital deployment priorities, specifically balancing R&D expansion, commercial investments, and M&A.

A: CEO Chris Viehbacher emphasized that while commercial teams for existing assets are established, lupus requires significant education investment. He stated that external M&A is currently opportunistic, focusing on DC-to-Phase 1B assets which are more capital-efficient. He cautioned against further large-scale distractions, prioritizing digestion of current changes and internal growth over aggressive external deals.

Q: Analyst asked about sizing the Cutaneous Lupus (CLE) opportunity relative to Systemic Lupus (SLE) and the distinct nature of these markets.

A: Alicia Alimo clarified they are separate opportunities: CLE affects ~250,000 patients (mostly dermatology-managed) and is 'life-changing,' while SLE affects ~300,000 (rheumatology-managed) and is 'life-ending.' CLE has <5% treatment penetration. The strategy involves empowering dermatologists to treat earlier to prevent irreversible scarring, differing from the rheumatologist-led approach in SLE.